14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
GH vs TEM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GH Captures Overall Composite Edge (51.3 HOLD vs 43.5 HOLD), While TEM Leads 4–2 on Growth & Valuation Pillars
GH Overall Winner
6-Pillar Tally: GH 2 – 4 TEM
Matrix Metrics: GH 6 – 2 TEM
As of Nov 17, 2026, Guardant Health, Inc. (GH) captures the overall head-to-head institutional edge over Tempus AI, Inc. (TEM) on higher Unified Composite conviction (51.3/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while TEM wins 4–2 across the 6-pillar growth and valuation breakdown. GH trades at $143.28 (N/M Forward P/E, -39.4% operating margin) versus TEM at $63.43 (N/M Forward P/E, -18.5% operating margin).
Growth vs. Quality Trade-Off: GH earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. TEM 43.5/100 HOLD) and 1.31β · 55% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.0); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $20.5B market capitalization and -39.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
TEM Moat ProfileEcosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment83.0% of Rev ($1.25B)
90D Engineering Disclosures0 Published · AI Drug Discovery
Investor FAQ GH vs TEM Key Questions & Quantitative Answers
As of Nov 17, 2026, Guardant Health, Inc. (GH) captures the overall head-to-head institutional edge over Tempus AI, Inc. (TEM) on higher Unified Composite conviction (51.3/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while TEM wins 4–2 across the 6-pillar growth and valuation breakdown. GH trades at $143.28 (N/M Forward P/E, -39.4% operating margin) versus TEM at $63.43 (N/M Forward P/E, -18.5% operating margin). Growth vs. Quality Trade-Off: GH earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. TEM 43.5/100 HOLD) and 1.31β · 55% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.0); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GH leads the Growth & Scale pillar: GH posts +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin), compared with TEM at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GH cumulative revenue shifted +988.9% while TEM shifted +296.9%. In operating R&D and SG&A reinvestment, GH deploys N/A (0 90-day corporate R&D disclosures) versus 83.0% of Rev ($1.25B) (0 disclosures) for TEM.
TEM screens cheaper on headline valuation multiples. GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin), whereas TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GH (0.0% ROE) versus TEM (-37.5% ROE) capital efficiency.
In options market volatility and institutional positioning, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 7.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 55% Vol realized risk). By comparison, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.